Oscar Health (NYSE:OSCR) Rating Increased to Strong-Buy at Wall Street Zen

Oscar Health (NYSE:OSCR) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Sunday.

OSCR has been the subject of a number of other reports. UBS Group increased their price target on Oscar Health from $15.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Barclays upgraded Oscar Health from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $30.00 to $35.00 in a research note on Wednesday. Robert W. Baird increased their price target on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Wolfe Research initiated coverage on Oscar Health in a research note on Tuesday, May 5th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings upgraded Oscar Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Oscar Health has an average rating of “Hold” and a consensus price target of $20.78.

Oscar Health Trading Down 2.1%

Shares of NYSE OSCR opened at $28.29 on Friday. The business has a fifty day moving average price of $20.05 and a 200 day moving average price of $16.55. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11. Oscar Health has a 1-year low of $10.69 and a 1-year high of $29.42. The stock has a market capitalization of $8.53 billion, a P/E ratio of -47.95, a price-to-earnings-growth ratio of 1.98 and a beta of 2.37.

Oscar Health (NYSE:OSCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The company had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.90 billion. During the same period last year, the business posted $0.92 earnings per share. The firm’s revenue was up 52.6% compared to the same quarter last year. Equities research analysts expect that Oscar Health will post 0.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Janet Liang sold 12,475 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total value of $273,701.50. Following the transaction, the insider directly owned 259,057 shares of the company’s stock, valued at approximately $5,683,710.58. This represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam Mcananey sold 9,859 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total value of $216,306.46. Following the completion of the transaction, the insider directly owned 218,096 shares in the company, valued at $4,785,026.24. This represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 189,660 shares of company stock valued at $4,283,140. Insiders own 24.39% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Oscar Health by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after purchasing an additional 540,851 shares during the period. Geode Capital Management LLC increased its holdings in shares of Oscar Health by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 4,798,313 shares of the company’s stock valued at $68,964,000 after purchasing an additional 116,430 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Oscar Health by 1,097.8% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 237,882 shares of the company’s stock valued at $3,418,000 after purchasing an additional 218,022 shares during the period. BIT Capital GmbH grew its holdings in Oscar Health by 545.0% during the fourth quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after acquiring an additional 5,227,152 shares during the period. Finally, Farallon Capital Management LLC grew its holdings in Oscar Health by 146.5% during the third quarter. Farallon Capital Management LLC now owns 3,639,000 shares of the company’s stock worth $68,886,000 after acquiring an additional 2,163,000 shares during the period. 75.70% of the stock is owned by institutional investors and hedge funds.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.